Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.96 USD
+0.06 (6.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.94 -0.02 (-2.10%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 221 - 240 ( 326 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ZFN In Vivo Protein Replacement Preclinical Data Suggests to Us a Potential Cure for Lysosomal Storage Diseases; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY 2014 Financials: Long Cash Runway and Clinical Catalysts in 2015; Reiterate OUTPERFORM and Increase PT to $30 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA-Approved IND Supports 2015 Initiation for Clinical Testing of Zinc Finger Gene Editing to Cure Beta-Thalassemia; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
February and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2015 Pipeline Update; Program in Beta Thalassemia Set to Initiate in H1:15; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In-licensed Nanoparticle Technology Expands Indications for in vivo ZFN Genome Editing; Reiterate OUTPERFORM and $29 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In-licensed Nanoparticle Technology Expands Indications for in vivo ZFN Genome Editing; Reiterate OUTPERFORM and $29 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
January and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sangamo''s Gene Editing In-Vivo Protein Replacement Platform Shows Promise in Preclinical Studies; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
December and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
If Sangamo Can Repeat The Huntington''s Preclinical Results in Patients, We Anticipate a Major Breakthrough; Reiterate OUTPERFORM and $29 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
If Sangamo Can Repeat The Huntington''s Preclinical Results in Patients, We Anticipate a Major Breakthrough; Reiterate OUTPERFORM and $29 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gearing up for a Catalyst Rich 2015; Reiterate OUTPERFORM and Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
October and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hemophilia A and B Programs Are Moving Forward, Expect First IND Submission in Q2:15; Reiterate OUTPERFORM and $28 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ICAAC Update: Five Patients Are Now off HIV Drugs after SB-728-T Treatment. Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
September and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L